Skip to content
This GLP
By This GLP Editorial Team · Updated September 2026A price with no period

Ascend Medical review

Two package prices are published and neither states what period they cover.

The verdict

Ascend Medical publishes a Starting Package at $225 for semaglutide and $240 for tirzepatide. Neither states a period. Not per month, not per supply. Neither figure is ranked here.

Disclosure: This GLP is reader-supported. Some links below are affiliate links — if you start care through them we may earn a commission, at no extra cost to you. The order on this page is not commercial, and a commission never changes what we write about a provider. How we make money.

Category
GLP-1 telehealth
Molecule
Semaglutide · Tirzepatide
Form
Injection
States
2
Prescription
Required
Compounded
Yes — not FDA-approved

Ascend Medical sells both molecules by injection. Two packages carry a figure. Coverage is recorded in two states.

  1. Who writes the prescription, and what do they see?

    A prescription precedes dispensing. The pages name packages rather than clinicians. The intake is not documented. Nor is the duration of what is being sold.

    A package price without a period is not comparable to anything. Two sellers quoting $225 are quoting different products if one covers four weeks and the other twelve. Ascend does not say which it is.

  2. What happens when the dose goes up?

    Nothing is published about dose. That question sits underneath the first one. Neither the duration nor the dose is stated. A package like that cannot be priced per milligram or per month.

  3. What the price includes

    No figure here can be turned into a monthly cost. $225 might be a month, a supply, or a starting block. The pages do not say. Ask before ordering, and get the answer in writing. Until then, treat both numbers as quotes rather than prices.

  4. What it claims, and what it cites

    Both lines are compounded. A pharmacy prepares them. The FDA does not review them before dispensing. No pharmacy is named.

Where it holds up, and where it does not

  • Strength: Two packages carry a published figure
  • Strength: Both molecules are offered
  • Strength: The word Starting is at least stated
  • Limitation: No billing period appears anywhere
  • Limitation: Neither figure can be compared
  • Limitation: Coverage is recorded in two states
  • Limitation: No dose information is published

What the evidence says about this kind of treatment

The assessment above is about Ascend Medical. These are about the drugs it sells, and they are traced to the primary literature.

Right for
A reader prepared to ask what period the package covers before ordering.
Wrong for
A reader who needs a monthly figure to compare against another seller.

The evidence behind what Ascend Medical prescribes

These studies examine the medicines, not this provider. Results with approved products do not establish the quality or effectiveness of a seller’s compounded formulation.

How Ascend Medical compares

SellerWho it suitsGo
Balanced Hormone HealthReaders who would rather see a dose increase priced than hidden in a monthly figureSee Balanced Hormone Health →
CeliaRxReaders who prefer a one-time purchase to a subscription and can fund it at onceSee CeliaRx →
Blue Sky MDPatients near the practice who will ask what enrollment costs before joiningSee Blue Sky MD →
Compare all providers side by side →

More GLP-1 telehealth sellers reviews: Good Girl RxGood Life MedsGoodRxGreen Cap HealthHarborHarmony Wellness Clinic

Sponsored alternative

SkinnyRx

Readers choosing tirzepatide, the one line with a published standing rate

Check SkinnyRx availability →

Frequently asked

Is $225 a monthly price?
Unknown. Ascend states no period beside either figure — not per month, not per supply.
Why is nothing ranked here?
A price with no period cannot be compared. Ranking it would put a number on a board that means something different from every other number on it.
Where does Ascend operate?
Coverage is recorded in two states.
This GLP Editorial TeamPublisher · Updated September 2026

How this was assessed. The four questions above are answered from Ascend Medical’s own publicly-stated model, against the published editorial methodology. No ratings are fabricated and no first-hand outcomes are claimed. A partnership never changes the assessment — see how we make money.